Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca Plc (ADR) (AZN) Offloads Two Diabetes Drugs to Focus on Core Therapeutic Areas

AstraZeneca Plc (ADR) (NYSE:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary of 3SBio, in China. The exclusive licensing agreement is for the sale of the company’s two diabetes drugs Byetta and Bydureon.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Licensing Terms

AstraZeneca Plc (ADR) (NYSE:AZN) is to continue manufacturing and supplying the drugs for sale, under the terms of the agreement. The company can cancel the agreement should 3SBio fail to achieve the agreed sales targets.

The company is also entitled to a $50 million upfront payment that could be worth an additional $50 million on the Chinese firm winning import approval for two Bydureon formulations. The agreement provides the UK-based Pharma an opportunity to attract more sales on the drugs given that diabetes affects one in every 10 adults in China.

Inking deals with Chinese, company’s has turned out to be Astra’s main play as it continues to explore growth in the communist nation. Last year it entered a strategic alliance with WuXi AppTec for the production of biologic drugs.

AstraZeneca offloading commercial rights for the two diabetes drugs has however not gone well with some investors. Diabetes is one of the company’s core areas of focus. By issuing such rights the company will not be able to generate all the returns had it pursued sales on its own. The company on its defense insists such agreements allow it to expand its footprint in emerging markets.

Trimming Non-Core Areas

The giant pharmaceutical company has not enjoyed much success with the two diabetes drugs in China. Last year alone, it made less than $15 million on the two compared to $896 million generated from global sales of diabetes drugs.

Handing over the commercialization rights to a local entity could help the company focus its attention in other areas with greater opportunity for growth. Respiratory is one of the areas that have emerged as a soft spot when it comes to sales.

Impressive sales on respiratory drugs allowed the company to post an 11% increase in sales in the first half of the year. Building on the momentum appears to be the company’s main play heading into 2017.

AstraZeneca Plc (ADR) (NYSE:AZN) stock remained unchanged even on the signing of the commercialization agreement having rallied by 0.13% to close Thursday trading session at $30.84 a share.

Follow Astrazeneca Plc (NYSE:AZN)
Trade (NYSE:AZN) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!